Actively Recruiting
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
Led by Chen Xiaoping · Updated on 2025-12-02
200
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
For early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection. However, ablation is demanding on the surgeon and patients often face early recurrence if ablation is not complete. Therefore, it is necessary to find reasonable adjuvant treatment to consolidate the effect of microwave therapy.
CONDITIONS
Official Title
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years
- Diagnosed with hepatocellular carcinoma (HCC), Barcelona Clinic Liver Cancer (BCLC) stage 0-A
- No evidence of cancer outside the liver
- No tumor recurrence seen on scans 2 to 4 weeks after ablation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Child-Pugh liver function grade A or B with adequate blood and organ function
You will not qualify if you...
- History of other malignant tumors or recurrent HCC
- Previous treatment for HCC including local or systemic therapies
- Active or recent serious infections, autoimmune diseases, or immune deficiency
- Ongoing serious complications related to ablation
- Esophageal or gastric variceal bleeding within the past 6 months
- Unable or unwilling to comply with treatment and monitoring requirements
- Participation in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Wuhan, China, 430000
Actively Recruiting
Research Team
W
WanGuang D Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here